“上市热潮”+“政策支持”助力创新药提质向新，恒生创新药ETF(159316)连续获资金布局

Group 1 - Several innovative pharmaceutical companies received positive news regarding product launches in July, including Betta Pharmaceuticals' approval of Tazemetostat capsules for breast cancer, classified as a category 1 innovative drug [1] - Ascentage Pharma's self-developed Bcl-2 selective inhibitor, Lisenglitazone, received conditional approval, becoming the first Bcl-2 inhibitor approved in China for the treatment of adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [1] - The support for innovative drug policies remains strong, with the National Healthcare Security Administration's Director Wang Xiaoning stating that high-level innovative drugs will be supported to achieve returns that correspond to high investment and risk during the initial market phase [1] Group 2 - The government is implementing measures to facilitate the rapid clinical introduction of new drugs, including a streamlined approval process where one province can handle applications from multiple regions [1]